摘要
目的探讨培美曲塞联合PC化疗方案治疗晚期肺腺癌的效果及对血清癌胚抗原和半乳糖凝集素1(Gal-1)水平的影响。方法选取2015年1月至2017年12月扬州友好医院收治的100例晚期肺腺癌患者,依据随机数字表法分为观察组和对照组,每组50例。对照组使用PC化疗方案进行治疗,观察组使用培美曲塞联合PC化疗方案治疗,2组均以21 d为1个周期,治疗4个周期。观察2组患者肿瘤控制率,血清癌胚抗原、Gal-1水平,T细胞亚群水平以及不良反应发生情况。结果治疗后,观察组肿瘤控制率高于对照组[48.0%(24/50)比32.0%(16/50)](P=0.04)。治疗后,2组血清癌胚抗原、Gal-1水平均明显低于治疗前,且观察组明显低于对照组,2组CD_3^+、CD_4^+、CD_8^+水平和CD_4^+/CD_8^+比值均明显高于治疗前,且观察组均明显高于对照组,差异均有统计学意义(均P <0. 05)。2组治疗期间恶心呕吐、静脉炎、肝功能异常发生率比较差异均无统计学意义(均P>0. 05)。结论培美曲塞联合PC化疗方案治疗晚期肺腺癌,能降低血清癌胚抗原、Gal-1水平,提高患者免疫能力,增加患者的肿瘤控制率,且安全性较好。
Objective To explore the effect of pemetrexed combined with PC chemotherapy on advanced lung adenoeareinoma,serum careinoembryonie antigen (CEA)and galeetin-1(Gal-1).Methods From January 2015to December 2017,100 patients with advanced lung adenoeareinoma in Friendliness Hospital Yangzhou were randomly divided into observation group and control group,with 50 eases in each group.The control group was treated with PC chemotherapy;the observation group was treated with PC chemotherapy combined with pemetrexed;one course was 21d;both groups were treated for4courses.Tumor control rate,CEA,Gal-1,T cell subsets and adverse reactions were analyzed.Results After treatment,tumor control rate in the observation group was significantly higher than that in the control group[48.0%(24/50)vs 32.0%(16/50)](P =0.04).Levels of selalm CEA and Gal-1decreased after treatment in both groups;the levels in the observation group were significantly lower than those in the control group (P <0.05).CD3^+,CD4^+,CD8^+and CD4^+/CD8^+ increased after treatment ;the levels in the observation group were significantly higher than those in the control group(P <0.05).There was no significant difference of adverse reactions between groups (P >0.05).Conclusion PC chemotherapy combined with pemetrexed treating advanced lung adenoeareinoma can effectively reduce serum CEA and Gal-1,enhance immunocompetcnee and increase the tumor control rate with a good safety.
作者
顾玉琴
华燕艳
李杰
Gu Yuqin;Hua Yanyan;Li Jie(Department of Internal Medicine,Friendliness Hospital Yangzhou,Jiangsu Province,Yangzhou 225009,China;Department of Oneology,Affiliated Hospital of Jiangnan University,Jiangsu Province,Wuxi 214062,China)
出处
《中国医药》
2018年第12期1826-1829,共4页
China Medicine
基金
江苏省卫生和计划生育委员会科研课题(Q201615)~~
作者简介
通信作者:华燕艳,Email:guyuqing@163.com.
